Estonia’s University of Tartu developed BMVision, an AI tool that detects kidney cancer faster and more accurately, supporting radiologists without replacing them.
Researchers from the University of Tartu in Estonia have developed an artificial intelligence-based tool capable of accelerating the detection of kidney cancer and improving the accuracy of its diagnosis, according to a scientific study published in the journal "Communications Medicine".
The tool, called "BMVision," uses machine learning techniques to analyze computed tomography (CT) images, helping radiologists detect malignant and benign lesions faster and more reliably, including in cases where scans were not originally performed to look for tumors.
In a retrospective study conducted at the University Hospital of Tartu , six radiologists reviewed 200 CT scans, each in two ways, with and without artificial intelligence , resulting in 2,400 individual readings.
The results showed that using the AI-powered tool reduced the time required to identify, measure, and report malignant tumors by about a third, with a marked improvement in measurement accuracy and agreement among physicians.
The researchers emphasized that this technology is not intended to replace the radiologist, but rather to support him in light of the increasing global shortage of specialists and the rising volume of medical imaging examinations.
In this context, Associate Professor of Artificial Intelligence and Co-founder of Better Medicine, Dmytro Fishman, said, "This study reinforces the growing evidence that modern AI tools, developed in research laboratories, are capable of making a real impact on clinical practice and supporting physicians in their daily work."
For her part, Professor of Radiology at Tartu University Hospital, Dr. Pilvi Elvis, explained that the introduction of this tool may contribute to improving the quality of diagnosis and early detection of kidney cancer, noting that “although the solution has so far been used for research purposes only, it is currently being integrated into the clinical workflow, with all abdominal CT scans to be processed in the future via the BMVision system.”
The "BMVision" tool has received the European Conformity Mark (CE), confirming that it meets the safety, health and environmental standards adopted in the European Economic Area, thus becoming the first artificial intelligence tool available on the market that helps in the early detection and more accurate assessment of kidney cancer.
0 Comments